This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The infusion of tumor-specific T cells has been shown to eradicate solid tumors in animal models. These adoptive T cell strategies, however, have not translated into effective treatment of human cancer due to difficulties in expanding tumor antigen-specific T cells ex vivo, and the inability of infused T cells to persist for an extended period of time. However, recent studies have demonstrated improved clinical efficacy with the use of pre-infusion lymphodepleting chemotherapy and post-infusion IL-2. In addition, prior antigen-specific immunization results in increased T cell precursor frequencies and has been shown to augment ex vivo expansion. The purpose of this study is to (1) assess the feasibility of ex vivo expansion of HER2 specific T cells, and (2) to evaluate the safety of infusing ex vivo expanded HER2 specific T cells in patients with advanced stage HER2 expressing cancers. This is a dose escalation trial testing three doses of HER2 specific T cell infusions administered with or without IL-2 therapy.
Showing the most recent 10 out of 563 publications